US Patent

US9333204 — Solid antiviral dosage forms

Method of Use · Assigned to AbbVie Inc · Expires 2035-01-02 · 9y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects solid dosage forms containing antiviral compounds and methods for using these forms to treat antiviral infections.

USPTO Abstract

The present disclosure relates to solid dosage forms comprising antiviral compounds and methods of using such dosage forms to treat antiviral infection.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1889`	—

Patent Metadata

Patent number: US9333204
Jurisdiction: US
Classification: Method of Use
Expires: 2035-01-02
Drug substance claim: No
Drug product claim: Yes
Assignee: AbbVie Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.